NextPlat Corp Common Stock (NXPL)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at NextPlat and see a small, loss-making healthcare and e-commerce business with a market value of $24.4 million at the 2026-10-13 close of $9.00. The filed numbers show the challenge: in fiscal FY2025, the year ended 2025-12-31, revenue was $54.3 million and net loss was $10.5 million; in fiscal FY2024, revenue was $66.1 million and net loss was $14.0 million. So sales shrank, though the loss narrowed. The latest filed quarter is better: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $11.9 million and net loss was just $144,000. But one near-breakeven quarter does not prove durable profitability. Free cash flow is negative at roughly $-4.6 million on a trailing basis, and the FairStock Altman Z-Score is -0.80, which points to financial stress. The balance sheet has low debt-to-equity of 0.10, a modest positive, but the company still consumes cash. Valuation is not comforting: FairStock's P/B is 1.49 and its P/E is negative, so there is no earnings-based bargain here. The FairStock score of 37/100 and no Lynch category because of losses in each of the last four years tell me this remains a speculative turnaround, not a proven compounding machine. I would need evidence of stable revenue, positive free cash flow, and several profitable quarters before calling the business strong.

In plain English: NextPlat runs pharmacy and online shopping businesses. The company is losing money and its sales have been shrinking, though the latest quarter was close to breaking even. At $9.00 a share, the price does not look like a clear bargain because the business has not shown steady profits or cash generation.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer